2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
Zificsak, Craig A; Theroff, Jay P; Aimone, Lisa D; Albom, Mark S; Angeles, Thelma S; Brown, Rebecca A; Galinis, Deborah; Grobelny, Jennifer V; Herbertz, Torsten; Husten, Jean; Kocsis, Laura S; LoSardo, Christine; Miknyoczki, Sheila J; Murthy, Seetha; Rolon-Steele, Damaris; Underiner, Ted L; Wells-Knecht, Kevin J; Worrell, Candace S; Zeigler, Kelli S; Dorsey, Bruce D.
Bioorg Med Chem Lett
; 21(2): 660-3, 2011 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-21190849
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
Discovery of fluorescent 3-heteroarylcoumarin derivatives as novel inhibitors of anaplastic lymphoma kinase.
Simple Determination of Plasma Ponatinib Concentration Using HPLC.
Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
Determination of a novel anticancer c-Met inhibitor LS-177 in rat plasma and tissues with a validated UPLC-MS/MS method: application to pharmacokinetics and tissue distribution study.
Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors.
Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.